HIF2 and endocrine neoplasia: an evolving story

    1. Eamonn R Maher1,2
    1. 1Department of Medical Genetics, University of Cambridge, Cambridge, UK and
      2Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Research Campus, Cambridge CB2 0QQ, UK
    1. (Correspondence should be addressed to E R Maher; Email: erm1000{at}medschl.cam.ac.uk)


    In this issue of Endocrine-Related Cancer, Toledo et al. report the identification of activating mutations in the HIF2 (EPAS1) transcription factor in a subset of sporadic pheochromocytomas and paragangliomas. These findings add significantly to an evolving and complex story of the role of hypoxic gene response pathways in human endocrine neoplasia.

    • Revision received 23 April 2013
    • Accepted 25 April 2013
    • Made available online as an Accepted Preprint 7 May 2013
    | Table of Contents